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We evaluated all ABCC6 missense variants from ClinVar, from literature and novel 
variants from in-house patient screenings. In total, 235 variants were analysed 
using the numerical score-based variant classification system Sherloc (Nykamp et 
al. 2017). Clinical and functional evidence were scored with benign (B) or 
pathogenic (P) points using hierarchical decision trees and classification was based 
on the variant’s total score (Fig 1). To distinguish between different types of class 3 
variants we created subclasses for variants with a likely benign (LB), likely 
pathogenic (LP) or unclear (U) tendency (Fig 2b). We evaluated the same variants 
using guidelines from Sherloc’s forerunner, the ACMG-AMP classification system 
(Richards et al. 2015), and compared the outcome of both (Fig 2a). The 
interpretation of variants submitted in ClinVar was also compared with the 
corresponding result after applying Sherloc (Fig 3). Finally, the distribution of 
variants along the protein domains was investigated (Fig 4).
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Introduction
Pseudoxanthoma elasticum (PXE) is an ectopic mineralization disorder aﬀecting 
the elastic fibers of the skin, the eye and the cardiovascular system. It is caused by 
biallelic mutations leading to loss-of-function of the ABCC6 gene. To date, over 
400 genetic variants have been reported in ABCC6. However, high phenotypic 
variability, a lack of genotype-phenotype correlations and contemporary population 
genomics raise the question whether all these variants are pathogenic. Especially 
for missense substitutions it is challenging to predict the impact on protein 
function. We therefore systematically evaluated previously reported and novel 
ABCC6 missense variants and classified them according to pathogenicity, using a 
standardised approach.
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Conclusions
Evaluation of ABCC6 missense variants using the most recent and comprehensive 
criteria reveals an overestimation of (likely) pathogenic variants in literature 
and databases. Data that are missing for many variants are experimental validation 
and - surprisingly - segregation data. Our results underline that variant classification 
should be done systematically and with caution, as variant interpretation has 
important consequences for patients and carriers identified via familial or 
expanded carrier screening. The high number of class 3 variants confirms the 
need for functional testing to prove or refute their causality before returning them to 
patients. 
Fig 4. The transporter is characterised by two transmembrane domains (TMD), two 
linkers (L), two nucleotide binding domains (NBD) with Walker motifs (A and B) and a 
PDZ-like sequence. More variants reside in the C-terminal side of the protein, 
especially in TMD2 that contains the intracellular loop 8 (ICL8). This domain also 
seems to harbour more class 3 LP, class 4 and class 5 variants than any other 
domain.
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Fig 1. Evaluation and scoring of clinical and functional evidence with benign (B) or 
pathogenic (P) points leads to classification of the variant based on its total score. 
Subclasses of class 3, that originally do not exist in Sherloc, were created to highlight 
those variants on the verge of class 2 (class 3 LB) or 4 (class 3 LP). If conflicting 
evidence was used, a hierarchical approach (not shown) was followed to determine 
which evidence type is more decisive.
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Sherloc classifies variants based on point thresholds
Fig 2. (a) 235 variants were classified using the Sherloc (yellow) or ACMG-AMP (blue) 
framework. Class 3 variants were was most abundant, followed by class 4 & 5. Few 
class 1 or 2 variants were found. (b) Subclassification of Sherloc’s class 3 variants 
revealed a significant amount of uncertain variants with a likely pathogenic tendency 
(3 LP).
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Fig 3. (a) The Venn diagram represents the number of variants reported as benign (B), 
likely benign (LB), uncertain (U), likely pathogenic (LP) and/or pathogenic (P) in ClinVar 
(215 in total). Some variants have multiple interpretations and are considered 
conflicting when (L)B interpretations co-occur with (L)P interpretations or when U co-
occurs with (L)B/(L)P. (b) In contrast to the reported interpretations, the majority of 
these variants is classified as U using Sherloc. The percentage of conflicting (C) results 
in Sherloc is 0, because conflicting evidence is handled by a hierarchical approach. 
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